Smith+Nephew Personalizes Robotic-assisted Surgery for Patients and Surgeons With Launch of CORIOGRAPH Pre-Operative Planning and Modeling Services Exclusively for the CORI Surgical System
Smith+Nephew Personalizes Robotic-assisted Surgery for Patients and Surgeons With Launch of CORIOGRAPH Pre-Operative Planning and Modeling Services Exclusively for the CORI Surgical System
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of its new CORIOGRAPH Pre-Operative Planning and Modeling Services, providing an unparalleled, personalized solution for surgeons and patients across partial and total knee arthroplasty procedures. It is exclusively for use with the CORI Surgical System - the only orthopaedic robotic-assisted system to offer either intraoperative image-free or image-based registration, enabling the surgeon to choose whether or not to perform a pre-operative MRI scan.
今天,全球医疗技术公司Smith+Nephew (LSE:SN,NYSE:SNN) 宣布推出全新的CORIOGRAPH预操作计划和建模服务,为部分和全膝关节置换手术的医生和患者提供了一个无与伦比的个性化解决方案。该服务专门用于CORI手术系统,该系统是唯一提供术中无图像或基于图像注册的骨科机器人辅助系统,让外科医生选择是否进行预操作MRI扫描。
Delivering solutions for differing patient types coupled with planning and execution tools is essential to personalizing surgery. Robotic-assisted surgery can improve accuracy and reproducibility, and may lead to better patient outcomes compared to conventional techniques.1-3
个性化手术需要提供适合不同患者类型的解决方案,并配备计划和执行工具。机器人辅助手术可以提高准确性和可重复性,并可能导致比传统技术更好的患者结果。1-3
The first procedures using CORIOGRAPH Pre-Operative Planning and Modeling Services and RI.KNEE ROBOTICS 3.0 Software were recently completed by Dr. Steven Haas, Orthopaedic Surgeon and Chief of Knee Service at the Hospital for Special Surgery in New York. He stated, "We are now truly personalizing surgery and advancing efficiencies with RI.KNEE 3.0 and CORIOGRAPH services. Providing the ability to choose the right imaging modality represents the next paradigm for individualized patient care and brings orthopaedic robotics to another level."
纽约特别手术医院膝关节服务主任、骨科医生斯蒂文·哈斯博士最近完成了首批使用CORIOGRAPH境前计划建模服务和RI.KNEE机器人3.0软件的手术。他说:“我们现在正在真正个性化手术,并通过RI.KNEE3.0和CORIOGRAPH服务推进效率。提供选择合适成像模式的能力代表个性化患者护理的下一个范式,将骨科机器人技术带到另一个水平。”
The CORI Surgical System offers proprietary tools and AI-driven software across the full suite of procedure solutions to deliver a robotics platform that is flexible and scalable across joint arthroplasty indications. Built on 15+ years of clinical expertise and over 350,000 image-based surgery plans, CORIOGRAPH Pre-Operative Planning and Modeling Services is where the surgical journey begins. It is designed to optimize procedures and enable intraoperative efficiencies in conjunction with new RI.KNEE ROBOTICS 3.0 Software, which includes:
CORI手术系统提供专有工具和AI驱动软件,覆盖全套手术解决方案,以提供灵活且可扩展的跨关节置换指标机器人平台。基于15年以上的临床经验和超过35万次基于影像的手术计划,CORIOGRAPH预操作计划和建模服务是手术旅程的起点。它旨在优化手术,并与新的RI.KNEE机器人3.0软件相结合,实现术中效率,其中包括:
- Image-agnostic registration functionality, including image-based and image-free offerings
- Optimized knee offering with support for pre-cut tensioning with the CORI Digital Tensioner for partial, total and revision knees
- 不受影像限制的注册功能,包括基于影像和无图像的选择
- CORI数字张力器支持部分、全膝和修复的预切割应力优化膝关节手术
"The introduction of CORIOGRAPH Pre-Operative Planning and Modeling Services signals the next big step in personalized surgery and the evolution of our robotics ecosystem. This combined with the CORI Digital Tensioner will further advance efficiencies for robotic-assisted procedures," said Mayank Shandil, SVP, Global Marketing – Reconstruction and Robotics at Smith+Nephew.
Smith+Nephew全球重建和机器人业务的高级副总裁Mayank Shandil表示:“推出CORIOGRAPH境前计划和建模服务标志着个性化手术和我们机器人生态系统的演进的下一个重大步骤。与CORI数字张力器相结合,将进一步提高机器人辅助手术的效率。”
To learn more about the CORI Surgical System and Smith+Nephew's digital surgery applications across a range of joint arthroplasty indications, please visit
欲了解CORI手术系统和Smith+Nephew在关节置换不同指标下数字手术应用的更多信息,请访问
- ends –
- 结束 -
Enquiries
Media
Dave Snyder +1 (978) 749-1440
Smith+Nephew david.snyder@smith-nephew.com
咨询
媒体
Dave Snyder +1 (978) 749-1440
Smith+Nephewdavid.snyder@smith-nephew.com
References
参考
- Matsumoto T, Nakano N, Hayashi S, et al. Prosthetic orientation, limb alignment, and soft tissue balance with bi-cruciate stabilized total knee arthroplasty: a comparison between the handheld robot and conventional techniques. International Orthopaedics 2023;47(6):1473-80. doi: 10.1007/s00264-023-05737-6
- Crizer MP, Haffar A, Battenberg A, et al. Robotic Assistance in Unicompartmental Knee Arthroplasty Results in Superior Early Functional Recovery and Is More Likely to Meet Patient Expectations. Advances in Orthopedics 2021;2021 doi: 10.1155/2021/4770960
- Negrín R, Duboy J, Iñiguez M, et al. Robotic-assisted vs conventional surgery in medial unicompartmental knee arthroplasty: a clinical and radiological study. Knee Surg Relat Res 2021;33(1):5. doi: 10.1186/s43019-021-00087-2 [published Online First: 2021/02/14]
- Matsumoto T、Nakano N、Hayashi S等。 装置取向、肢体对齐和双十字韧带稳定全膝关节置换术:手持机器人和常规技术的比较。 International Orthopaedics 2023;47(6):1473-80。 doi:10.1007/s00264-023-05737-6
- Crizer MP,Haffar A,Battenberg A等。 在单节间接膝关节置换术中使用机器人辅助手术可以更好地恢复早期的功能,并且更有可能达到患者的期望。骨科进展2021年;2021 doi:10.1155/2021/4770960
- Negrín R,Duboy J,Iñiguez M等。 在内侧单节间接膝关节置换术中使用机器人辅助手术:临床和放射学研究。Knee Surg Relat Res2021年;33(1):5。 doi:10.1186/s43019-021-00087-2 [2021年2月14日发表的在线首次:]
About Smith+Nephew
关于史密斯和内修
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 18,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
史密斯和内修是一个投资组合医疗技术企业,专注于软和硬组织的修复、再生和替换。我们的存在旨在通过使用技术消除生活的限制,恢复人们的身体和自信心。我们称这个目的为“无限生活”。我们的18000名员工每天执行着这个任务,通过我们产品组合的卓越性,以及在我们的三个全球业务板块——骨科、运动医学与耳鼻喉科以及先进创伤管理中发明和应用新技术,改变着病患的生命。
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.5 billion in 2023. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
成立于1856年于英国赫尔,如今我们在100多个国家和地区开展业务,2023年的年销售额达55亿美元。史密斯和内修是富时100指数的成分股(LSE:SN, NYSE:SNN)。“集团”和“史密斯和内修”一词,除非上下文另有说明,否则均指Smith & Nephew plc及其合并子公司。
For more information about Smith+Nephew, please visit and follow us on X, LinkedIn, Instagram or Facebook.
欲了解更多史密斯和内修的信息,请访问并关注我们X, LinkedIn, Instagram或。Facebook.
Forward-looking Statements
前瞻性声明
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC's website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.
本文件可能含有前瞻性声明,这些声明有可能正确也有可能不正确。例如,关于预期的收入增长和交易利润率,市场趋势和产品管道的声明是前瞻性的陈述。像“目的”,“计划”,“打算”,“预计”,“有希望”,“相信”,“估计”,“期望”,“目标”,“考虑”和类似的表述通常旨在确定前瞻性声明。前瞻性声明涉及已知和未知的风险、不确定性和其他重大因素,这些因素可能导致实际结果与声明所表达的内容不同。对于史密斯和内修而言,这些因素包括:欧洲和中东的冲突,我们服务市场的经济和金融状况,特别是那些影响医疗保健提供商、付款方和客户的因素;已知和创新医疗设备的价格水平;医疗技术的发展;监管批准、偿付和其他政府行动;产品缺陷或召回或质量管理系统问题或未执行相关法规;与专利或其他索赔相关的诉讼;法律和金融合规风险及相关的调查、纠正或执法行动;我们供应链或供应商的运营中断;对有资质的人员的竞争;战略行动,包括收购和处置,我们在进行尽职调查、估值和整合已收购企业方面的成功度;不利于我们营业计划或组织调整的交易或其他变化导致的中断,以适应市场的发展;与医疗保健专业人士的关系;对信息技术和网络安全的依赖;由于自然灾害、天气和气候变化事件引起的中断;客户和其他利益相关方可持续性预期的变化;税收法规的变化;汇率波动的影响;以及影响我们或我们所在市场的政治、经济、商业、竞争或信誉方面的众多其他事项。请参阅史密斯和内修已依据美国证券交易委员会修正后的美国证券交易法案提交的文件,其中包括史密斯和内修的最新年度报告20-F表,在SEC的网站上www.sec.gov上讨论了其中某些因素。任何前瞻性声明均基于史密斯和内修截至声明日期可获得的信息。所有文本或口头前瞻性声明均应受到此警告的限制。史密斯和内修不承担更新或修订任何前瞻性声明以反映任何情况或史密斯和内修的期望的任何变化的任何责任。
◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.
◊ 史密斯和内修的商标。在美国专利和商标局注册的某些商标。